Company Overview
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Recent Developments
- Dec 2025 Revenue of $149.50M (-0.3% YoY); net profit $-74.62M.
- Trailing 12 Months Year-on-year growth — revenue +378.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 7.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 7.10% |
| 1 Year: | 378.00% |
Stock Price Performance
| 1 Year: | +160.24% |
| 6 Months: | +83.05% |
| 3 Months: | +11.34% |
| 1 Month: | +6.93% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)56.10 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MGNX MacroGenics, Inc. PHARMA | 4.32 | -2.72 | $275.18M | 0.00% | -34.08% | - | 7.10% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.48M | 71.28M | 6.72M | 14.68M | 8.18M | 2.85M | 80.67M | 3.25M | 5.11M | 2.06M | 1.67M | 1.66M | 152.36M | 4.70M | 18.83M | 20.80M | 15.79M | 9.66M | 10.59M | 18.74M | 25.19M | 13.68M | 20.26M | 18.25M | 16.88M | 30.76M | 15.66M | 11.10M | 26.01M | 41.73M | 24.50M | 13.14M | 10.40M | 9.10M | 10.80M | 110.71M | 13.19M | 22.24M | 72.84M | 20.77M |
| Operating Income | - | 45.13M | -21.29M | -15.44M | - | -30.63M | 40.09M | -34.27M | - | -38.21M | -41.18M | -47.72M | - | -50.21M | -44.31M | -35.00M | - | -47.62M | -52.97M | -37.94M | - | -45.45M | -47.31M | -36.13M | -51.29M | -40.28M | -52.99M | -66.64M | -41.81M | -24.95M | -38.43M | -44.96M | -35.50M | -53.75M | -58.18M | 54.19M | -42.62M | -36.76M | 18.64M | -33.44M |
| Net Income | -19.02M | 45.13M | -21.38M | -15.44M | -28.45M | -30.36M | 40.46M | -33.85M | -34.78M | -37.66M | -40.65M | -47.04M | 105.73M | -49.54M | -43.24M | -34.03M | -44.64M | -45.02M | -31.77M | -44.63M | -30.40M | -44.72M | -46.88M | -36.04M | -51.27M | -39.94M | -52.89M | -66.44M | -41.30M | -24.81M | -38.01M | 57.47M | 17.55M | -52.19M | -55.66M | 56.31M | -41.04M | -36.25M | 16.82M | -36.77M |
| Diluted EPS | - | 1.42 | -0.71 | -0.46 | -0.83 | -0.88 | 1.12 | -0.97 | -1.00 | -1.08 | -1.14 | -1.28 | 2.80 | - | - | - | - | - | - | - | - | - | -0.94 | -0.66 | -0.90 | -0.66 | -0.86 | -1.08 | -0.67 | -0.40 | -0.61 | 0.92 | 0.28 | -0.84 | -0.89 | 0.90 | -0.65 | -0.57 | 0.27 | -0.58 |
| R&D Expense | - | 21.46M | 22.66M | 24.10M | - | 27.35M | 33.34M | 30.30M | - | 32.80M | 34.46M | 40.98M | - | 45.67M | 52.01M | 46.22M | - | 47.06M | 51.44M | 44.85M | - | 48.89M | 57.35M | 44.66M | 53.12M | 55.78M | 49.82M | 61.44M | 51.74M | 48.19M | 45.87M | 43.23M | 30.13M | 46.03M | 51.73M | 40.54M | 39.70M | 40.79M | 32.71M | 34.97M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 57.21M | 63.83M | 58.03M | 47.80M | 100.85M | 91.88M | 157.74M | 60.12M | 64.19M | 104.88M | 77.45M | 151.94M | 58.75M | 149.96M | 149.50M |
| Operating Income | 5.25M | 8.21M | 366.00K | -38.31M | -20.18M | -60.04M | -22.14M | -171.21M | -177.19M | -131.06M | -202.79M | -121.42M | -168.24M | -110.58M | -72.84M |
| Net Income | 6.72M | 8.36M | -261.00K | -38.31M | -20.14M | -58.53M | -19.63M | -171.45M | -151.81M | -129.74M | -202.12M | -119.76M | -9.06M | -66.97M | -74.62M |
| Diluted EPS | 0.00 | 0.00 | -0.04 | -1.40 | - | - | - | - | - | -2.47 | -3.37 | -1.95 | -0.15 | -1.07 | -1.18 |
| R&D Expense | 41.09M | 45.43M | 46.58M | 70.19M | 98.27M | 122.09M | 147.23M | 190.83M | 195.31M | 193.20M | 214.58M | 207.03M | 166.58M | 177.19M | 147.17M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 53.75M | 125.78M | 173.89M | 359.27M | 311.26M | 373.88M | 332.13M | 312.50M | 378.74M | 335.25M | 280.47M | 298.42M | 261.65M | 256.85M |
| Total Equity | -38.63M | -17.48M | -8.24M | 78.91M | 121.29M | 313.34M | 268.75M | 299.24M | 242.88M | 230.63M | 295.88M | 239.62M | 142.01M | 152.61M | 116.06M | 55.59M |
| Cash & Equivalents | 36.88M | 55.22M | 47.74M | 116.48M | 157.59M | 196.17M | 84.10M | 211.73M | 220.13M | 126.47M | 181.13M | 123.47M | 108.88M | 100.96M | 182.84M | 57.22M |
| Total Liabilities | - | - | 61.98M | 46.87M | 52.60M | 45.93M | 42.51M | 74.64M | 89.25M | 81.87M | 82.86M | 95.63M | 138.46M | 145.81M | 145.60M | 201.25M |
| Current Liabilities | - | - | 29.73M | 28.82M | 27.09M | 24.20M | 27.30M | 49.76M | 59.94M | 45.17M | 50.67M | 74.58M | 48.61M | 56.11M | 55.53M | 43.12M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 6.76M | -6.58M | -14.17M | - | - | - | 14.40M | -153.23M | -134.27M | -111.90M | -143.83M | -86.96M | -78.20M | -68.37M | -81.04M |
| Investing Cash Flow | -500.21K | -940.04K | -2.96M | - | - | - | 77.88M | 56.64M | -79.36M | -7.79M | -36.61M | 70.72M | -80.08M | 149.30M | -114.10M |
| Financing Cash Flow | 12.09M | 46.83K | 85.87M | - | - | - | 35.35M | 104.99M | 119.97M | 174.34M | 122.78M | 1.66M | 150.36M | 960.00K | 69.51M |
| Capital Expenditure | -500.21K | -940.00K | -2.96M | -3.57M | -9.20M | -11.38M | -29.40M | -24.95M | -4.29M | -5.91M | -6.20M | -3.62M | -1.76M | -3.71M | -1.91M |
| Free Cash Flow | 6.26M | -7.52M | -17.13M | - | - | - | -15.00M | -178.19M | -138.56M | -117.80M | -150.03M | -90.58M | -79.97M | -72.08M | -82.95M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 9.2% | 12.9% | 0.6% | -80.2% | -20.0% | -65.3% | -14.0% | -284.8% | -276.0% | -125.0% | -261.9% | -79.9% | -286.4% | -73.7% | -48.7% |
| Net Margin % | 11.7% | 13.1% | -0.4% | -80.2% | -20.0% | -63.7% | -12.4% | -285.2% | -236.5% | -123.7% | -261.0% | -78.8% | -15.4% | -44.7% | -49.9% |
| ROE % | -38.4% | -101.5% | -0.3% | -31.6% | -6.4% | -21.8% | -6.6% | -70.6% | -65.8% | -43.8% | -84.3% | -84.3% | -5.9% | -57.7% | -134.2% |
| ROCE % | - | 34.2% | 0.4% | -26.1% | -6.0% | -21.1% | -6.8% | -62.9% | -66.3% | -39.9% | -77.8% | -52.4% | -69.4% | -53.6% | -34.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 7.86% | 5.01M | $20.73M |
| 2 | Blackrock Inc. | 7.35% | 4.68M | $19.37M |
| 3 | Vanguard Capital Management LLC | 4.17% | 2.66M | $11.00M |
| 4 | Renaissance Technologies, LLC | 4.13% | 2.63M | $10.90M |
| 5 | Acadian Asset Management. LLC | 3.99% | 2.54M | $10.53M |
| 6 | Bank of America Corporation | 3.91% | 2.49M | $10.30M |
| 7 | Two Sigma Investments, LP | 3.87% | 2.47M | $10.21M |
| 8 | Millennium Management Llc | 3.73% | 2.37M | $9.83M |
| 9 | Wasatch Advisors LP | 3.17% | 2.02M | $8.36M |
| 10 | RA Capital Management, L.P. | 2.93% | 1.86M | $7.72M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MGNX
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQZzNlN1htYjJoYUJOcG5JRXU1V25rU1BYVFZIZXd0NmF4eEwtMnRkMTZseDM1SUdxQ05ySE1yLTJxRXZzWlFsR0pncTZRd2RGNXlia0w4aUllRVVuVEIxYWc3Qno2bXFfaUpLUzg3T2UzZWc2SG5oNHFRLWN2VzlKQlo5d3Fady1zNUhWWk…
MacroGenics (MGNX) Stock Faces A Revenue Reality Check After Deeper Losses - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxQZHZiQTZHaDQ4eDNuTmxZaXhqZ3NhbVJ1N1BzUllTcnRueDZDY1lpbXBmdkpuZGwtNHpaMmVhMDg2SF8wdEIwZGVtbll2V0xOczdQWnBvYkkxanR5d3Z1RGhYczdLWkpZOExKMlhHZXpnUDQxdWZpT09WQnJUb203Vkw5b0x4dHZfbHJCQT…
MGNX Stock Hits 16-Month High, But This Analyst Sees Another 140% Potential Upside - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxOSHVwTW5GX1ZUV2N6enVOS0NJNndCMi1jUUFWOVV1SzB4a3BYZGwtWEVoS0cxczB3YUF3ZU9LcXBJZkV1YWxrQk5UNFRJbVNZeFExdXBwdGZGaDZycXBRXzNta29xazhia0NIUjZJYmpOOHFreDFaTW1YYW9VZ3J4bW0xSmgyTENPTHVqWn…
MGNX Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE8wRzlvR3l5ekNnRFc5QmE4YnhKQ3pudkwzTkRxcDEteXJCblJtRnR6RnVzUkZ1WnkzSkNKQXI3eVhyWEVSRFpIbTRIcnl2MGtXNkNyaVpvOWI4YTJjeTFsU1BqOFplNnlaV1JLRGgtVzJ1My0xUGQzWVVB?oc=5" target="_blank">MGN…
Sanofi’s TZIELD approval triggers $24.5M payment to MacroGenics - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOQzhzVzBwa1p0eTlGOGx3SnBYd2xtS1g2eGhtVVRxQ3VPdlVhWlIybTd6WEdVNmZLZUl3QVdYOE9pRnR2OXNqd09pVXVTd29fMHJaLVJKcm9CSzVCWndVdkJMOVo0a2VIbkxyU19uTWh6QXJzR2hzaGdTQ2YyeDU3S2lHVUtUZlhveU1ldz…
MacroGenics stock drops after FDA partial hold (MGNX:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxNZi1ualFzWVoxNzJGOVA2bUk0bFQzX1pxSFA2VWpLbWlPYThQNzZmcGt0Q2w1WWo0bXpmQ3ptOUs5OUhRMkxSRTFnMmhIMkxoejVsWXRJcVd5bFB1NjV6Z0QtQ19FV0huZktRdXpJS1ljRjhubHl5a1Z5TUZsLWZKREJ3S2Q?oc=5" targ…
MGNX — Frequently Asked Questions
What is the current share price of MacroGenics, Inc. (MGNX)?
As of 2026-09-19 21:16 PDT, MacroGenics, Inc. (MGNX) trades at $4.32 on NasdaqGS. Its 52-week range is $1.33 to $4.86.
What is the market capitalisation of MGNX?
MacroGenics, Inc. (MGNX) has a market capitalisation of $275.18M on NasdaqGS.
What is the P/E ratio of MGNX?
MGNX trades at a trailing price-to-earnings (P/E) ratio of -2.72. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 6.14.
Is MGNX a good stock to buy?
This page provides a data-driven analysis of MacroGenics, Inc. (MGNX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.